Niacinamide–Ceramide Conjugate: In Vitro Bioactivities and 28-Day Clinical Evidence for Multitarget Skincare

Abstract Niacinamide (NAM) and ceramides are well-established skincare ingredients with distinct yet complementary biological mechanisms. Nevertheless, simple physical blending of these two actives presents practical limitations for topical application. To address this, the present study evaluated SuperCera N-Nicotinamide(P) (NAM-Cer), a niacinamide–ceramide covalent conjugate conceived to integrate bioactivities derived from each parent moiety within a single molecular framework. Employing an integrated workflow combining in vitro cellular assays and a 28-day randomized clinical trial, we identified multiple cellular-level bioactivities of NAM-Cer, including elastase inhibition, upregulation of type I collagen (COL1A1) and aquaporin-3 (AQP3), suppression of melanogenesis and tyrosinase activity, and downregulation of matrix metalloproteinase-1 (MMP-1). Clinical evaluation revealed significant, concentration-dependent improvements in skin hydration, elasticity, firmness, brightness, and antiwrinkle efficacy, along with favorable cutaneous tolerability. In summary, NAM-Cer is a safe, multitarget skincare candidate that elicits diverse skin-beneficial bioactivities in vitro and drives concentration-dependent cutaneous improvements in short-term human topical use.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-16
DOI
https://doi.org/10.1021/acsomega.6c05537
Primary Topic
Skin Protection and Aging
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Niacinamide–Ceramide Conjugate: In Vitro Bioactivities and 28-Day Clinical Evidence for Multitarget Skincare

Ping Zhao, Haoquan Yu, Chaowen Yang, Zijian Xu et al.
6 links
ACS Omega
Skin Protection and Aging
article

Niacinamide–Ceramide Conjugate: In Vitro Bioactivities and 28-Day Clinical Evidence for Multitarget Skincare

Ping Zhao, Haoquan Yu, Chaowen Yang, Zijian Xu, Yanqiu Mu, Ziheng Zhang, Jingmin Feng
article en

Abstract

Abstract Niacinamide (NAM) and ceramides are well-established skincare ingredients with distinct yet complementary biological mechanisms. Nevertheless, simple physical blending of these two actives presents practical limitations for topical application. To address this, the present study evaluated SuperCera N-Nicotinamide(P) (NAM-Cer), a niacinamide–ceramide covalent conjugate conceived to integrate bioactivities derived from each parent moiety within a single molecular framework. Employing an integrated workflow combining in vitro cellular assays and a 28-day randomized clinical trial, we identified multiple cellular-level bioactivities of NAM-Cer, including elastase inhibition, upregulation of type I collagen (COL1A1) and aquaporin-3 (AQP3), suppression of melanogenesis and tyrosinase activity, and downregulation of matrix metalloproteinase-1 (MMP-1). Clinical evaluation revealed significant, concentration-dependent improvements in skin hydration, elasticity, firmness, brightness, and antiwrinkle efficacy, along with favorable cutaneous tolerability. In summary, NAM-Cer is a safe, multitarget skincare candidate that elicits diverse skin-beneficial bioactivities in vitro and drives concentration-dependent cutaneous improvements in short-term human topical use.

ACS Omega
Guangdong Pharmaceutical University (CN)
Guangdong Pharmaceutical University, Department of Education of Guangdong Province
Good health and well-being
Skin Protection and Aging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon